SureNano Science Ltd (SURE) AI Stock Analysis

• Market Cap: C$7.89M
• Dividend Yield: N/A
• Average Volume (3M): 666.00
• Price to Earnings (P/E): ―
• Beta (1Y): -3.37
• Revenue Growth: N/A
• EPS Growth: 91.27%
• Country: CA
• Employees: N/A
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): >-0.01
• Shares Outstanding: 23,907,800
• 10 Day Avg. Volume: 950
• 30 Day Avg. Volume: 666
• PEG Ratio: 0.37
• Price to Book (P/B): -21.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.31 ▲(4.67% Upside)

The score is primarily held down by very weak financial performance (zero recent revenue, ongoing losses and cash burn, and negative equity). Technicals provide partial support due to a strong uptrend, but overbought signals raise near-term risk. Recent financing improves liquidity somewhat, while valuation remains unattractive due to continued losses and no dividend.

Positive Factors

Recent Financing

The recent $1.25 million financing improves SureNano's liquidity, supporting operational expenses and market expansion, which can enhance long-term operational capabilities.

Potential Acquisition

The potential acquisition of GlucaPharm could diversify SureNano's product portfolio into high-demand areas like diabetes treatment, offering long-term growth opportunities.

Incentive Alignment

Stock options granted to key personnel align management incentives with company growth, potentially driving long-term strategic execution and value creation.

Negative Factors

Negative Equity

Negative equity indicates accumulated losses and a weakened capital base, increasing reliance on external funding and limiting financial flexibility.

Cash Flow Issues

Consistently negative cash flow suggests ongoing cash burn, indicating the company is not self-sustaining and reliant on external capital for operations.

Zero Revenue

Zero revenue over recent years limits the company's ability to cover costs and achieve profitability, posing a significant challenge to long-term viability.

SureNano Science Ltd Business Overview & Revenue Model

Company Description

SureNano Science Ltd. operates as a nanotechnology supply company in Canada and Colorado, the United States. The company distributes SureNano surfactant, a ready-to-mix food-grade compound that provides the base for high performance hemp and cannabis nano-emulsions. Its SureNano surfactant has applications in products, such as CBD, hemp-infused sprays, beverages, food items, and tropical products. The company was incorporated in 2021 and is headquartered in Vancouver, Canada.

How the Company Makes Money

SureNano Science Ltd generates revenue through the commercialization of its proprietary nanotechnology solutions. Key revenue streams include the sale of nanomaterials and related products to industrial clients, licensing agreements for its patented technologies, and collaborative partnerships with other companies for joint development projects. The company may also receive funding from grants or research partnerships aimed at advancing nanotechnology applications. Significant partnerships with industry leaders or research institutions can enhance its market reach and contribute to its earnings.

SureNano Science Ltd Financial Statement Overview

Summary

SureNano Science Ltd is experiencing significant financial difficulties, with no revenue generation and continued operational losses. The balance sheet reflects financial instability with negative equity, despite having no debt. Persistent negative cash flows indicate ongoing challenges in sustaining operations and generating cash.

Income Statement

SureNano Science Ltd has consistently reported zero total revenue in recent periods, indicating a complete lack of sales activity. Gross profit, EBIT, and EBITDA margins are all negative, highlighting substantial operational losses. There is no revenue growth, further indicating challenges in business expansion or market penetration.

Balance Sheet

The company's balance sheet shows negative stockholders' equity, suggesting financial instability and potential insolvency risks. The absence of debt is a positive aspect, reducing leverage risks. However, substantial liabilities relative to assets and negative equity highlight severe financial distress.

Cash Flow

Operating and free cash flows are negative, indicating cash outflows due to operating activities without sufficient income. The operating cash flow to net income ratio is not meaningful due to negative figures. The lack of capital expenditures suggests limited investment in growth or future projects.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	18.00K	36.00K
Gross Profit	-1.88K	-2.50K	-2.50K	-3.75K	16.51K	34.66K
EBITDA	-135.01K	-57.09K	-277.39K	-380.27K	-1.12M	-81.59K
Net Income	45.49K	-59.59K	-279.89K	-384.02K	-1.12M	-82.51K
Balance Sheet
Total Assets	118.97K	54.27K	153.11K	317.61K	686.44K	966.81K
Cash, Cash Equivalents and Short-Term Investments	74.43K	23.49K	134.80K	276.99K	667.09K	929.01K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	61.01K	134.04K	173.29K	57.90K	36.49K	17.32K
Stockholders Equity	57.96K	-79.77K	-20.18K	259.71K	649.95K	949.49K
Cash Flow
Free Cash Flow	-169.04K	-161.31K	-142.19K	-403.63K	-669.76K	-102.99K
Operating Cash Flow	-169.04K	-161.31K	-142.19K	-383.63K	-669.76K	-102.99K
Investing Cash Flow	0.00	0.00	0.00	-6.47K	0.00	0.00
Financing Cash Flow	220.00K	50.00K	0.00	0.00	407.85K	1.03M

SureNano Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SURE, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.21, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 62.11 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:SURE.

SureNano Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
HG	54 Neutral	C$1.11B	-117.73	-87.47%	―	331.08%	15.77%
GMG	49 Neutral	C$328.58M	-34.40	-92.59%	―	6.29%	-3.71%
CNO	47 Neutral	C$17.78M	-12.37	-61.05%	―	-15.84%	-375.96%
SURE	46 Neutral	C$7.89M	-300.00	―	―	―	91.27%
IZ	45 Neutral	C$424.07K	100.00	―	―	109.13%	―

SureNano Science Ltd Corporate Events

SureNano Science Ltd. Grants 1.5 Million Stock Options to Key Personnel

SureNano Science Ltd. has announced the granting of 1,500,000 stock options to its directors, officers, and consultants. These options, which vest immediately, are exercisable at CAD $0.18 per share over five years, representing 4.4% of the company’s outstanding common shares. This move is likely aimed at incentivizing key personnel and aligning their interests with the company’s growth objectives.

SureNano Science Ltd. Completes $1.25 Million Private Placement

SureNano Science Ltd. has successfully closed a $1,250,000 private placement, issuing 10,000,000 units at $0.125 per unit. Each unit includes a common share and a warrant, with warrants allowing purchase of additional shares at $0.35 within 24 months. The funds raised will support operating expenses, market expansion for the SureNano™ surfactant, and potential business combinations or acquisitions, enhancing the company’s operational capabilities and market positioning.

SureNano Explores Acquisition of GlucaPharm for Diabetes Drug Development

SureNano Science Ltd. has entered into a non-binding letter of intent with GlucaPharm Inc. to explore a potential acquisition. GlucaPharm holds exclusive rights to develop a novel GLP-1 compound, GEP-44, aimed at treating diabetes and obesity with fewer side effects than existing treatments. If the acquisition proceeds, SureNano will acquire all of GlucaPharm’s shares through a share exchange, with GlucaPharm shareholders owning less than 20% of SureNano. SureNano also announced a private placement to raise up to $1.25 million for operational expenses and market exploration, including potential investments like GlucaPharm.

SureNano Science Ltd. Announces $1.25 Million Private Placement

SureNano Science Ltd. has announced a private placement aiming to raise up to $1,250,000 through the sale of 10,000,000 units, each comprising one common share and one purchase warrant. The proceeds will be used for operating expenses and exploring new markets for its SureNano™ surfactant, potentially impacting the company’s market reach and operational capabilities.